Concussion

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Oregon TherapeuticsFrance - Paris

1 program

Brain 101 websitePhase 2

Human BioSciencesWV - Martinsburg

1 program

Brain 101 websitePhase 21 trial

Active Trials

NCT01978795Completed25Est. Feb 2012

Neuren PharmaceuticalsAustralia - Camberwell

1 program

NNZ-2566Phase 21 trial

Active Trials

NCT02100150Terminated32Est. Jun 2016

SPARK BiopharmaKorea - Seoul

1 program

EEG Diagnostic for Repetitive Sub-concussive Head ImpactsN/A1 trial

Active Trials

NCT05562544Completed42Est. Feb 2023

Impact TherapeuticsChina - Shanghai

1 program

NormativeN/A1 trial

Active Trials

NCT05551520Unknown1,437Est. Oct 2024

Forte BiosciencesTX - Dallas

1 program

Voice recordingN/A1 trial

Active Trials

NCT02069795Completed50Est. Aug 2014

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

Neuren PharmaceuticalsNNZ-2566

Human BioSciencesBrain 101 website

SPARK BiopharmaEEG Diagnostic for Repetitive Sub-concussive Head Impacts

Impact TherapeuticsNormative

Forte BiosciencesVoice recording

Clinical Trials (5)

Total enrollment: 1,586 patients across 5 trials

NCT02100150 Neuren PharmaceuticalsNNZ-2566

A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)

Start: Sep 2014Est. completion: Jun 201632 patients

Phase 2Terminated

NCT01978795 Human BioSciencesBrain 101 website

Interactive Training in Sports Concussion Prevention and Management

Start: Aug 2011Est. completion: Feb 201225 patients

Phase 2Completed

NCT05562544 SPARK BiopharmaEEG Diagnostic for Repetitive Sub-concussive Head Impacts

EEG Diagnostic for Repetitive Sub-concussive Head Impacts

Start: Sep 2022Est. completion: Feb 202342 patients

N/ACompleted

NCT05551520 Impact TherapeuticsNormative

ImPACT Version 4-Touchscreen: Normative and Reliability Study

Start: Feb 2022Est. completion: Oct 20241,437 patients

N/AUnknown

NCT02069795 Forte BiosciencesVoice recording

Speech Analysis as a Diagnostic Tool for Mild Traumatic Brain Injury

Start: Feb 2014Est. completion: Aug 201450 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.